Probiotics in IBD: Evidence and Perspectives on Patient Health and Disease Management.

2025-09-17
International journal of molecular sciences 26(18)
- Emília Hijová

PubMed: 41009629
DOI: 10.3390/ijms26189065

Study Design

Type: Review
Population: human randomized clinical trials that evaluate the usefulness of various probiotics in relation to the treatment, prevention, and maintenance of disease remission
Methods: This review summarizes human randomized clinical trials that evaluate the usefulness of various probiotics in relation to the treatment, prevention, and maintenance of disease remission

Rigorous Journal

Inflammatory bowel disease (IBD) includes two distinct diseases: ulcerative colitis (UC) and Crohn's disease, affecting people worldwide regardless of age and gender. It appears that a combination of many factors, primarily genetic background, environmental, host immune response, and a state of reduced microbial diversity are associated with IBD. Gut modulation by probiotics application represents one of the potential strategies for the prevention or treatment of IBD. The gut microbiota has the ability to influence host physiology either directly or through microbial metabolites. This review summarizes human randomized clinical trials that evaluate the usefulness of various probiotics in relation to the treatment, prevention, and maintenance of disease remission.

Research Insights

Supplement	Dose	Health Outcome	Effect Type	Effect Size	Source
Bifidobacterium animalis subsp. lactis BB-12	—	Improved Effectiveness in Inflammatory Bowel Disease	Beneficial	Small	View source This review summarizes human randomized clinical trials that evaluate the usefulness of various probiotics in relation to the treatment, prevention, and maintenance of disease remission.
Bifidobacterium animalis subsp. lactis BB-12	—	No Clear Clinical Benefit	Neutral	Small	View source This review summarizes human randomized clinical trials that evaluate the usefulness of various probiotics in relation to the treatment, prevention, and maintenance of disease remission.
Bifidobacterium breve Bb-18	—	No Clear Clinical Benefit	Neutral	Small	View source This review summarizes human randomized clinical trials that evaluate the usefulness of various probiotics in relation to the treatment, prevention, and maintenance of disease remission.
Bifidobacterium longum infantis M-63	—	Improved Irritable Bowel Syndrome Symptoms	Beneficial	Moderate	View source Consumption of B. longum subsp. infantis M-63 significantly improved overall IBS symptoms, abdominal pain, abdominal distension, bowel movement satisfaction, and general condition in patients with IBS.
Bifidobacterium plantarum	—	Reduced Inflammatory Bowel Disease Symptoms	Beneficial	Small	View source This review summarizes human randomized clinical trials that evaluate the usefulness of various probiotics in relation to the treatment, prevention, and maintenance of disease remission.
Lactobacillus acidophilus L-92	—	Improved Allergic Symptoms	Beneficial	Moderate	View source Lactobacillus acidophilus L-92 has been reported to improve symptoms in patients with atopic dermatitis and allergic rhinitis in human studies.
Lactobacillus acidophilus LA1	—	Reduced Effects of Inflammatory Bowel Disease	Beneficial	Small	View source This review summarizes human randomized clinical trials that evaluate the usefulness of various probiotics in relation to the treatment, prevention, and maintenance of disease remission.